5-氨基-6-溴异喹啉 | 850198-02-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5-氨基-6-溴异喹啉
• 中文别名: 6-溴异喹啉-5-胺
• 英文名称: 6-Bromoisoquinolin-5-amine
• CAS: 850198-02-6
• 化学式: C₉H₇BrN₂
• 分子量: 223.072
• InChiKey: TZHVTCQPCFBQGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  6-溴-5-硝基异喹啉	6-bromo-5-nitroisoquinoline	850197-72-7	C9H5BrN2O2	253.055
  6-溴异喹啉	6-bromo-isoquinoline	34784-05-9	C9H6BrN	208.057

反应信息

• 作为反应物：
  描述：

  5-氨基-6-溴异喹啉 、 3-氧代环丁烷甲酸乙酯 在 四氯化钛 、 sodium cyanoborohydride 作用下， 以 二氯甲烷 为溶剂， 以29 %的产率得到ethyl 3-((6-bromoisoquinolin-5-yl)amino)cyclobutane-1-carboxylate
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2
• 作为产物：
  描述：

  6-溴异喹啉 在 硫酸 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 3.1h， 生成 5-氨基-6-溴异喹啉
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2

文献信息

• Kinase inhibitors
  申请人：——

  公开号：US20030187026A1

  公开（公告）日：2003-10-02

  Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

  具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
• Synthesis of Dibenzo[<i>b</i>,<i>f</i>]azepines via Palladium‐Catalyzed Cascade [4 + 3] Annulation of <i>o</i>‐Alkenyl Bromoarenes and <i>o</i>‐Bromoaniline Derivatives
  作者：Xin‐Chen Zhan、Guo‐Qiang Lin、Jian‐Guo Fu、Xiao‐Ming Ji、Shu‐Sheng Zhang、Chen‐Guo Feng

  DOI：10.1002/adsc.202300336

  日期：2023.12.5

  A cascade [4+3] annulation of o-alkenyl bromoarenes and o-bromoaniline derivatives was described. Various dibenzo[b,f]azepines with substitutions on the 10/11 position were obtained in 14–97% yields. The synthetic versatility of this protocol is highlighted by the preparation of a precursor of the drug molecule oxcarbazepine, a gram-scale synthesis, and two product transformations. Unlike previous

  描述了邻-烯基溴芳烃和邻-溴苯胺衍生物的级联[ 4+3]环化。获得了在 10/11 位点上有取代的各种二苯并[ b , f ]氮杂卓化合物，产率为 14-97%。该方案的合成多功能性通过药物分子奥卡西平前体的制备、克级合成和两种产品转化来突出。与之前的胺化/Heck 序列不同，该级联过程应该经历 C（乙烯基）、C（芳基）-钯环参与途径。
• 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Abbott Laboratories

  公开号：EP1463505A2

  公开（公告）日：2004-10-06
• US6831175B2
  申请人：——

  公开号：US6831175B2

  公开（公告）日：2004-12-14
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE
  申请人：ABBOTT LAB

  公开号：WO2003051366A2

  公开（公告）日：2003-06-26

  Compounds having the formula (I), are useful for inhibiting protein kinases and for the treatment of cancer. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.